Abbott实验室达到了预期的收益,提高了2025年的利润预测,并增加了红利。 Abbott Labs met earnings expectations, raised 2025 profit forecast, and boosted dividend.

Abbott实验室报告说,第二季度收入为每股1.30美元,达到预期水平,收入为113.7亿美元,比上一年增加6.9%。 Abbott Laboratories reported second-quarter earnings of $1.30 per share, meeting expectations, with $11.37 billion in revenue, up 6.9% year-over-year. 该公司将其2025年全年EPS指南提高到5.12至5.18美元,宣布季度股息为每股0.59美元,并保持了强劲的财政状况,市场上限为2 151.13亿美元,P/E比率为15.49。 The company raised its 2025 full-year EPS guidance to $5.12–$5.18, declared a quarterly dividend of $0.59 per share, and maintained a strong financial profile with a market cap of $215.13 billion and a P/E ratio of 15.49. 分析师将库存评为“机动购买”,一致商定价格目标为147.00美元。 Analysts rate the stock as a "Moderate Buy" with a consensus price target of $147.00. 机构投资者采取了混合行动,有些减少了股份,而其他投资者,包括黑文私人有限责任公司和Balentine有限责任公司,则增加了股份。 Institutional investors made mixed moves, with some reducing stakes while others, including Haven Private LLC and Balentine LLC, increased holdings. 股票交易额为12361美元,低于50天和200天的移动平均数。 The stock trades at $123.61, below its 50-day and 200-day moving averages.